<DOC>
	<DOC>NCT00754624</DOC>
	<brief_summary>Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005</brief_summary>
	<brief_title>An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial</brief_title>
	<detailed_description>This is an uncontrolled study without comparator. Subjects were followed up to 4 years on Technosphere Insulin. Of 229 subjects 199 were exposed for ≥12 mo, 175 for ≥ 24 mo, 60 for ≥ 36 mo, 31 for ≥ 42 mo, &amp; 2 for 48 mo.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Previous completion of PDCINS0008 or MKCTI005 Subjects must be able to attend all scheduled visits and, in the opinion of the Investigator, be able to complete this safety trial Subjects must be able to understand English or have access to validated primary language trial documents Written informed consent Drug or alcohol dependency Smokers (subjects are expected to remain nonsmokers throughout their participation in this trial) Known hypersensitivity to the trial drug or to drugs of similar chemical structures Anemia (hemoglobin level &lt; 11 g/dL for females or &lt; 12 g/dL for males) Evidence of moderate or greater ketones in urine Women of childbearing potential practicing inadequate birth control. (Adequate birth control is defined as using oral contraceptives, condoms or diaphragms with spermicide, intrauterine devices, DepoProvera, contraceptive patches or surgical sterilization) Women who are pregnant Clinically significant adverse events that remain unresolved from the previous trial and/or clinically significant abnormal laboratory values which are determined by the Investigator or the MKC Medical Monitor to be unsafe or confounding to continued participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>